Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KA Kineta (KA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends About Kineta Stock (NASDAQ:KA) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Kineta alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.57▼$0.8652-Week Range N/AVolume530,700 shsAverage Volume409,478 shsMarket Capitalization$7.04 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewKineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.Read More… Kineta Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks25th Percentile Overall ScoreKA MarketRank™: Kineta scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKineta has received no research coverage in the past 90 days.Read more about Kineta's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for KA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKineta does not currently pay a dividend.Dividend GrowthKineta does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for KA. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for KA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kineta insiders have not sold or bought any company stock.Percentage Held by Insiders23.70% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.32% of the stock of Kineta is held by institutions.Read more about Kineta's insider trading history. Receive KA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kineta and its competitors with MarketBeat's FREE daily newsletter. Email Address KA Stock News HeadlinesSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANTDecember 12, 2024 | prnewswire.comKineta and TuHURA Enter Acquisition AgreementNovember 25, 2024 | tipranks.comThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… December 22, 2024 | Crypto 101 Media (Ad)Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid TumorsOctober 18, 2024 | theglobeandmail.comKineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024October 4, 2024 | globenewswire.comKineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1October 2, 2024 | globenewswire.comKineta, Inc Transitioning from Nasdaq to OTC MarketsSeptember 19, 2024 | globenewswire.comKineta, Inc.: Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAugust 19, 2024 | finanznachrichten.deSee More Headlines KA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Kineta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kineta investors own include Intel (INTC), Motley Fool 100 Index ETF (TMFC), Argan (AGX), AST SpaceMobile (ASTS), AutoZone (AZO), Cadence Design Systems (CDNS) and Walt Disney (DIS). Company Calendar Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KA CUSIPN/A CIK1445283 Webwww.kinetabio.com Phone(206) 378-0400FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,100,000.00 Net MarginsN/A Pretax Margin-345.77% Return on Equity-1,044.95% Return on Assets-336.46% Debt Debt-to-Equity Ratio0.05 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$5.44 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / BookN/AMiscellaneous Outstanding Shares12,254,000Free Float9,350,000Market Cap$7.04 million OptionableNot Optionable Beta0.46 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:KA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kineta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KA Stock Alerts